The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 07, 2012

Filed:

May. 19, 2005
Applicants:

Frits J. Fallaux, Be Leiderdorp, NL;

Robert C. Hoeben, Be Leiden, NL;

Abraham Bout, AR Moerkapelle, NL;

Domenico Valerio, Leiden, NL;

Alex J. Van Der Eb, TW Oegstgeest, NL;

Govert Schoutten, Leiden, NL;

Inventors:

Frits J. Fallaux, Be Leiderdorp, NL;

Robert C. Hoeben, Be Leiden, NL;

Abraham Bout, AR Moerkapelle, NL;

Domenico Valerio, Leiden, NL;

Alex J. van der Eb, TW Oegstgeest, NL;

Govert Schoutten, Leiden, NL;

Assignee:

Crucell Holland B.V., Leiden, NL;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01N 63/00 (2006.01); C07H 21/02 (2006.01); C12N 5/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

Cells capable of at least, in part, complementing adenovirus an adenovirus defective in E2A function. Such cells include a nucleic acid-encoding adenovirus E2A or a functional part, derivative, temperature-sensitive mutation and/or analogue thereof, integrated into the cell's genome. Methods for producing an adenovirus particle/vector with a functional deletion of E2A are also disclosed. Such methods involve providing a cell with the functionally deleted adenovirus vector, culturing the cell, and harvesting viral particles. The functional deletion may comprise a deletion in E2A. The nucleic acid-encoding E2A in the cell's genome may lack sequence overlap with the vector, preventing formation of a replication-competent adenovirus or restoration of E2A function. The adenovirus vector may further include a functional deletion in the E1-region. Methods are disclosed for providing cells of an individual with a nucleic acid of interest, without risk of administering simultaneously a replication-competent adenovirus vector, comprising administering the individual an adenovirus vector described herein.


Find Patent Forward Citations

Loading…